相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia
Mark D. Danese et al.
BLOOD (2011)
Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy
Robert Griffiths et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
Robert Griffiths et al.
BMC CANCER (2010)
Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Veronica Fernandez et al.
CANCER RESEARCH (2010)
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Amy J. Davidoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Limits of observational data in determining outcomes from cancer therapy
Sharon H. Giordano et al.
CANCER (2008)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data
Michael E. Stokes et al.
VALUE IN HEALTH (2008)
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients
Carrie N. Klabunde et al.
ANNALS OF EPIDEMIOLOGY (2007)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
分享论文
